Suppr超能文献

对新冠病毒感染者嗅球和嗅束的神经病理学评估。

Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19.

作者信息

Lengacher Nathalie A, Tomlinson Julianna J, Jochum Ann-Kristin, Franz Jonas, Hasan Ali Omar, Flatz Lukas, Jochum Wolfram, Penninger Josef, Stadelmann Christine, Woulfe John M, Schlossmacher Michael G

机构信息

Neuroscience Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.

Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, 20815, USA.

出版信息

Acta Neuropathol Commun. 2024 May 3;12(1):70. doi: 10.1186/s40478-024-01761-8.

Abstract

The majority of patients with Parkinson disease (PD) experience a loss in their sense of smell and accumulate insoluble α-synuclein aggregates in their olfactory bulbs (OB). Subjects affected by a SARS-CoV-2-linked illness (COVID-19) also frequently experience hyposmia. We previously postulated that microglial activation as well as α-synuclein and tau misprocessing can occur during host responses following microbial encounters. Using semiquantitative measurements of immunohistochemical signals, we examined OB and olfactory tract specimens collected serially at autopsies between 2020 and 2023. Deceased subjects comprised 50 adults, which included COVID19 + patients (n = 22), individuals with Lewy body disease (e.g., PD; dementia with Lewy bodies (n = 6)), Alzheimer disease (AD; n = 3), and other neurodegenerative disorders (e.g., progressive supranuclear palsy (n = 2); multisystem atrophy (n = 1)). Further, we included neurologically healthy controls (n = 9), and added subjects with an inflammation-rich brain disorder as neurological controls (NCO; n = 7). When probing for microglial and histiocytic reactivity in the anterior olfactory nuclei (AON) by anti-CD68 immunostaining, scores were consistently elevated in NCO and AD cases. In contrast, microglial signals on average were not significantly altered in COVID19 + patients relative to healthy controls, although anti-CD68 reactivity in their OB and tracts declined with progression in age. Mild-to-moderate increases in phospho-α-synuclein and phospho-tau signals were detected in the AON of tauopathy- and synucleinopathy-afflicted brains, respectively, consistent with mixed pathology, as described by others. Lastly, when both sides were available for comparison in our case series, we saw no asymmetry in the degree of pathology of the left versus right OB and tracts. We concluded from our autopsy series that after a fatal course of COVID-19, microscopic changes in the rostral, intracranial portion of the olfactory circuitry -when present- reflected neurodegenerative processes seen elsewhere in the brain. In general, microglial reactivity correlated best with the degree of Alzheimer's-linked tauopathy and declined with progression of age in COVID19 + patients.

摘要

大多数帕金森病(PD)患者会出现嗅觉丧失,并在嗅球(OB)中积累不溶性α-突触核蛋白聚集体。感染与严重急性呼吸综合征冠状病毒2(SARS-CoV-2)相关疾病(新冠病毒病(COVID-19))的患者也经常出现嗅觉减退。我们之前推测,在宿主遭遇微生物后的反应过程中,可能会发生小胶质细胞活化以及α-突触核蛋白和tau蛋白的错误处理。我们使用免疫组化信号的半定量测量方法,检查了2020年至2023年尸检时连续采集的嗅球和嗅束标本。死者包括50名成年人,其中有新冠病毒病阳性患者(n = 22)、路易体病患者(如帕金森病;路易体痴呆(n = 6))、阿尔茨海默病(AD;n = 3)以及其他神经退行性疾病患者(如进行性核上性麻痹(n = 2);多系统萎缩(n = 1))。此外,我们纳入了神经功能正常的对照组(n = 9),并增加了患有炎症性脑部疾病的受试者作为神经对照组(NCO;n = 7)。通过抗CD68免疫染色检测前嗅核(AON)中的小胶质细胞和组织细胞反应性时,NCO组和AD组的评分持续升高。相比之下,尽管新冠病毒病阳性患者嗅球和嗅束中的抗CD68反应性随年龄增长而下降,但与健康对照组相比,其小胶质细胞信号平均没有显著变化。在tau蛋白病和突触核蛋白病患者的大脑AON中,分别检测到磷酸化α-突触核蛋白和磷酸化tau蛋白信号轻度至中度增加,这与其他人描述的混合病理情况一致。最后,在我们的病例系列中,当两侧均可进行比较时,我们发现左右嗅球和嗅束的病理程度没有不对称性。我们从尸检系列中得出结论,在经历致命的新冠病毒病病程后,嗅觉回路颅内近端部分的微观变化(如果存在)反映了大脑其他部位出现的神经退行性过程。一般来说,小胶质细胞反应性与阿尔茨海默病相关的tau蛋白病程度相关性最好,并且在新冠病毒病阳性患者中随年龄增长而下降。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8d3/11067107/542f842f317a/40478_2024_1761_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验